AMGN shares have rallied 8.6% post‑earnings, breaking above the $440 resistance and holding the 50‑day moving average, while cash flow metrics show a 15% QoQ improvement. The technical pattern suggests continued upward momentum, supporting a bullish outlook.

Investor sentiment is highly positive, driven by upbeat earnings and TEZSPIRE’s phase‑3 data, propelling AMGN into Dow‑Jones gainers. The narrative of strong pipeline progress reinforces a bullish market tone.

While recent catalysts reduce near‑term downside, long‑term risk remains tied to regulatory approvals and competition in biologics. Given improved cash flow and a diversified portfolio, the long‑term outlook stays bullish but warrants monitoring.

Volume spikes above 1.5 M shares and the RSI is at 68, confirming bullish momentum, while the MACD line has crossed above the signal line. These data‑driven indicators point to a likely continuation of the uptrend.